Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern J, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hock task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069–77.
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548–54.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–9.
Sharma S, Dixit V. Epilepsy – a comprehensive review. Int J Pharm Res Dev. 2013;2(12):61–80.
Karceski SC. Seizure medications and their side effects. Neurology. 2007;69(22):E27–9.
Sillanpaa M, Shinnar S. Long-term mortality in childhood-onset epilepsy. N Engl J Med. 2010;363(26):2522–6.
Racoosin JA, Feeney J, Burkhart G, Boehm G. Mortality in antiepileptic drug development programs. Neurology. 2001;56(4):514–9.
Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsy. 1995;36(Suppl. 1):3–13.
Sabaz M, Lawson JA, Cairns DR, Duchowny MS, Resnick TJ, Dean PM, et al. Validation of the quality of life in childhood epilepsy questionnaire in American epilepsy patients. Epilepsy Behav. 2003;4:680–91.
Lozano I. The therapeutic use of Cannabis sativa L. in Arabic medicine. Journal of Cannabis Therapeutics. 2001;1:63–70.
Pereira P. The elements of material medical and therapeutics. Philadelphia: Lea & Blanchard; 1843.
O’Shaughnessy WB. On the preparations of the Indian hemp, or gunjah (Cannabis indica). Transactions of the medical and physical society of Bengal; 1840:71–102.
Reynolds JR. Therapeutical uses and toxic effects of Candida indica. Lancet. 1868(1):637–8.
Gowers WR. Epilepsy and other chronic convulsive disorders. London: Churchill; 1881.
Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften. 1978;65:174–9.
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–9.
Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574–7.
Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55(6):783–6.
US Food and Drug Administration. Warning letters and test results. 2015–2019. https://www.fda.gov/news-events/public-health-focus/warning-letters-and-test-results-cannabidiol-related-products (Accessed July 6th, 2019).
Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Use of cannabidiol in the treatment of epilepsy: efficacy and security in clinical trials. Molecules. 2019;24:1459–74.
Pertee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol, and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2006;152(2):199–215.
Ross HR, Napier I, Connor M. Inhibition of recombinant human T-type calcium channels by Delta 9-tetrahydrocannabinol and cannabidiol. J Biol Chem. 2008;283:16124–34.
Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70:313–8.
Patel RR, Barbosa C, Brustovetsky T, Brustovestsky N, Cummins TR. Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol. Brain. 2016;139:2164–81.
Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–51.
Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al. Randomized, dose ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14).
•• Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–20. This pivotal clinical trial provided evidence of CBD efficacy as adjunctive therapy in Dravet syndrome assisting its eventual Federal Drug Administration (FDA)-approved indication for adjunctive therapy in this patient population.
•• Devinsky O, Patel AD, Cross JK, Villanueva V, Wirrell EC, Previtera M, et al. Effects of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888–97. This pivotal clinical trial provided evidence of CBD efficacy as adjunctive therapy for the treatment of drop seizures in Lennox Gastaut Syndrome assisting its eventual Federal Drug Administration (FDA)-approved indication for adjunctive therapy in this patient population.
Thiele EA, March ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96.
Szaflarski J, Bebin E, DeWolfe J, Dure L, Gaston T, Harsanyi K, et al. Seizure response to cannabidiol in a state-sponsored open-label program (S14.006). Neurology. 2016;86(16).
Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270–8.
Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, et al. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018;87:131–6.
• Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59(8). The results from this expanded access open-label program provide the largest published cohort to date of CBD use in a population of both children and adults with TREs providing important long-term safety and treatment effect data.
Sands TT, Rahdari S, Oldham MS, Caminha Nunes E, Tilton N, Cilio MR. Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: results from an expanded access program in the US. CNS Drugs. 2019;33(1):47–60.
Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2018:60(2).
Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvn LA, Bruno PL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis. Epilepsia. 2016;51(10):1617–24.
Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, et al. Open-label use of highly purified CBD (Epidiolex) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131–7.
Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017;32(1):35–40.
Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D. Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia. 2017;58(8):96–100.
Kaplan EH, Offermann EA, Sievers JW, Comi AM. Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome. Pediatr Neurol. 2017;71:18–23.
Morrison G, Crockett J, Blakey G, Sommerville K. A phase 1, Open-Label, Pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Am Coll Clin Pharmacol. 2019.
Gaston TE, Beben EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9).